Skip to content
跳至主要內容
SPY
···
QQQ
···
IWM
···
DIA
···
AAPL
···
MSFT
···
NVDA
···
GOOGL
···
AMZN
···
META
···
TSLA
···
BRK.B
···
JPM
···
GLD
···
TLT
···
BTC
···
ETH
···
VIXY
···
UUP
···
USO
···
SPY
···
QQQ
···
IWM
···
DIA
···
AAPL
···
MSFT
···
NVDA
···
GOOGL
···
AMZN
···
META
···
TSLA
···
BRK.B
···
JPM
···
GLD
···
TLT
···
BTC
···
ETH
···
VIXY
···
UUP
···
USO
···
Stock detail
Loading institutional stock data...
← BACK TO COCKPIT
ALL TICKERS →
OPTIONS CHAIN →
FATE
Fate Therapeutics, Inc.
NASDAQGM
Biotechnology
United States
$2.48
▲
+0.06 (+2.48%)
POST
—
OPEN
$2.38
HIGH
$2.49
LOW
$2.38
PREV CLOSE
$2.42
VOLUME
609.9K
0.21x avg
BID / ASK
1.91 / 3.28
spr 1.370
MARKET CAP
$297.2M
DAY RANGE
$2.38
$2.49
P/E (TTM)
—
Fwd -2.6
EPS (TTM)
-1.05
DIV YIELD
—
52W HIGH
$3.23
-23.2%
52W LOW
$0.9300
+166.7%
BETA
2.55
vs S&P 500
DES
FA
GP
OPT
HLDR
EARN
CMP
COMPARE
ASK DESK
AFTER-HOURS
$2.48
+0.00
(+0.00%)
LAST SURPRISE
—
—
NEXT EARNINGS
—
—
CATALYST
No fresh catalyst
—
ANALYST
—
—
SHORT INT
—
—
OPTIONS IV
—
—
FATE
$2.48
▲
+2.48%
Chart
Valuation
Financials
Peers
News
FATE · K 線技術分析（即時、可互動）
basic
pro
快速分析（約 90–120 秒）
Loading K-line chart…
按上方「快速分析」，研究台會以這張 K 線為起點跑一輪快速回答：三個分析師視角（總經、基本面、技術面）加交易計畫與風險統計，約 90–120 秒。想要五隊深度研究與機構級報告，請在研究台把模式切到「深度」。
1-YEAR PRICE
One-Year Trajectory
RISK-ON
252 BARS · +145.5% YOY
1-year price chart. Started at 1.01, currently 2.48, up 145.5 percent. Range 0.95 to 3.11 over 252 data points.
2025-09-05
$1.01 → $2.48 (+145.5%)
2026-09-04
§ Valuation
Loading § Valuation
§ Multi-Year Financials
Loading § Multi-Year Financials
§ Peers
Loading § Peers
§ Recent News
Loading § Recent News
EDITORIAL · NOT INVESTMENT ADVICE.
Data sources: Finnhub (quote / profile / news / peers) + Yahoo (stats) + SEC EDGAR XBRL (financials + DCF). All values cached for 5 minutes via ISR.
VALUATION
Deterministic Valuation (SEC EDGAR + Finnhub)
—
NO DCF
DCF Fair Value
—
DCF vs Spot
—
Comps Fair Value
$5.37
WACC Used
+7.0%
Terminal g
+3.5%
Verdict: hold
· peers $5.37 (+116.4%)
Peers:
IMRX
TLSI
PRTC.L
VNDA
MYGN
FHTX
NWBO
MGNX
⚠ DCF skipped: missing FCF or shares data from SEC EDGAR. Often the case for non-US issuers.
FINANCIALS
Multi-Year Financials (SEC XBRL)
RISK-OFF
YOY REV -51.2% · 3 FY
FY
Revenue
Net Income
OCF
FCF
Assets
2025-12
$6.6M
-$136.3M
-$106.1M
-$112.0M
$318.9M
2024-12
$13.6M
-$186.3M
-$122.9M
-$123.6M
$440.7M
2023-12
$63.5M
-$160.9M
-$132.3M
-$138.4M
$506.2M
PEERS
Sector & Industry Peers
CALM
10 PEERS · FINNHUB
IMRX
TLSI
PRTC.L
VNDA
MYGN
FHTX
NWBO
MGNX
CAMP
ANIK
NEWS
Recent News (past 14 days)
CALM
10 HEADLINES · LAST 14 DAYS
Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference
GlobeNewswire · 2026-09-03
Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts
BioPharma Dive · 2026-09-02
Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis
GlobeNewswire · 2026-08-14
Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates
Zacks · 2026-08-13
Fate Therapeutics: Q2 Earnings Snapshot
Associated Press · 2026-08-13
Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
GlobeNewswire · 2026-08-13
Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Misses Revenue Estimates
Zacks · 2026-08-06
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 2026-08-03